Xsolla Set to Launch the Xsolla StarNest Academy and Incubator Program in Baku
Collaboration in Azerbaijan Aims to Build a Thriving Game Development Ecosystem and Empower Local Talent with New Programs Launching in 2025
Xsolla, a global video game commerce company, has announced a strategic partnership with StarNest and Azerbaijan’s Innovation and Digital Development Agency (IDDA) to establish the Xsolla StarNest Academy and Incubator Program. This transformative collaboration was unveiled at the region's largest gaming festival, Gamesummit Winter Edition 2024, in Baku, Azerbaijan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209823866/en/
(Graphic: Xsolla)
Gamesummit Winter Edition 2024 spotlighted the growth of the gaming industry in Azerbaijan, featuring discussions on trends, global best practices, and presentations of locally developed games. At the festival, IDDA and Xsolla revealed plans to empower local developers, game designers, and studios with cutting-edge training, incubation and accelerator programs, and access to financial and technological resources. This partnership will redefine Azerbaijan's role in the global gaming industry while fostering local talent and innovation.
“This collaboration opens up extensive opportunities for implementing joint projects that will drive the development of Azerbaijan's gaming sector,” said Yevgeniya Bikmurzina, Head of IDDA's Innovation Ecosystem Department. “Azerbaijani game studios will have access to the tools and resources needed to make a mark in the global market.”
“This partnership represents a significant milestone for Xsolla as we collaborate with Azerbaijani leaders to unlock the region’s potential,” said Rytis Joseph Jan, SVP of Global Strategic Partnerships at Xsolla. “By combining our global expertise with the visionary leadership of our partners, we aim to empower the next generation of talent in Azerbaijan and drive meaningful innovation with global impact.”
Xsolla Incubator & Accelerator in Azerbaijan
The Xsolla Incubator and Accelerator will support Azerbaijan's game development community by providing tools, mentorship, and resources to turn ideas into successful projects. The Incubator will help early-stage developers refine concepts, gain technical expertise, and collaborate with international experts. The Accelerator will assist established studios in scaling their projects, offering access to funding, mentorship, and global industry connections. These programs aim to position Azerbaijan as a key player in the gaming industry, creating opportunities for local talent to succeed globally.
Xsolla StarNest Academy
The Xsolla StarNest Academy will provide 90 young individuals with specialized training in game development. Additionally, an incubation program will launch in 2025 to support local game studios, offering mentorship from international experts, access to financial resources, and opportunities to showcase games globally.
StarNest, an Azerbaijani telecommunications company, will lead efforts to secure a dedicated facility for the Academy, ensuring an environment conducive to growth and learning. IDDA will offer strategic oversight to align the initiative with Azerbaijan’s national goals for digital transformation.
Regional Headquarters
Xsolla is also exploring options to establish its regional headquarters for Central Asia in Baku to further support its commitment to the community and game developers in the region. Not only will it serve as a regional hub, but also a technology center for the leading edge development and support of its industry leading solutions.
With the Xsolla StarNest partnership this marks a new chapter for Azerbaijan’s gaming sector reflecting the shared vision to position the country as a regional game development and digital innovation leader.
This groundbreaking collaboration sets the stage for Azerbaijan to become a hub for gaming innovation and talent development. For more information, please visit: xsolla.blog/azerbaijan
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
About the Innovation and Digital Development Agency (IDDA)
IDDA is an Azerbaijani government agency specializing in digital diplomacy and analytics, offering research, training, and consultancy to enhance the digital presence of institutions. It plays a pivotal role in shaping modern diplomatic strategies through digital tools and data analysis.
For more information, visit idda.az
About StarNest
StarNest is a leading Azerbaijani telecommunications company providing internet and networking solutions, including broadband services, corporate connectivity, and IT infrastructure support. StarNest is dedicated to enabling technological growth and digital transformation across Azerbaijan.
For more information, visit starnest.io
About GameSummit
GameSummit is a prominent organization in Azerbaijan focused on the development of the gaming industry. Through events like Gamesummit Winter and Summer Editions, it creates opportunities for local game studios, promotes innovation, and raises awareness about career prospects in gaming and esports.
For more information, visit gamesummit.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209823866/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom